Kharkiv National Medical University, formerly known as Kharkiv Medical Institute and previously Kharkiv State Medical University, is a medical university in Kharkiv, Ukraine. In March 2022 many buildings were heavily damaged due to the Russian invasion into Ukraine.

During the past decade, GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 19 clinical trials were completed, i.e. on average, 65.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 17 clinical trials were completed. i.e. 340% of trials that started reached the finish line.

Out of the total clinical trials conducted in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Galapagos NV" with 4 trials sponsored, "Celgene" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine" are "Ulcerative Colitis" (9 trials), "Rheumatoid Arthritis" (6 trials), "Crohn Disease" (3 trials), "Arthritis, Rheumatoid" (2 trials) and "Diabetes Mellitus" (2 trials). Many other conditions were trialed in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine" in a lesser frequency.

Most popular intervention types in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine" are "Drug" (31 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Filgotinib" (4 trials), "Etrolizumab" (3 trials), "Adalimumab" (2 trials) and "BI 695501" (2 trials). Other intervention names were less common.

The vast majority of trials in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine" are 30 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine". undefined are not yet recruiting, 2 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".